Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The invention relates to method for typing a sample of an individual suffering from, or is suspected to suffer from, a progressive neurodegenerative disease. The invention further relates to methods for assigning a treatment of the individual, based on said typing.

Abstract: The present invention relates to an in vitro assay for measuring phosphorylated tau in a sample, said assay comprises the use of 2 antibodies i) a capture antibody specific for pS396 on tau and ii) a detection antibody binding tau on a different epitope that the capture antibody.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The present invention relates to a method for detecting an individual as being at risk of developing a neurodegenerative disease, the method comprising: a) measuring the amount or concentration of neurofilament-light (NfL) in a sample obtained from the individual; and b) detecting the individual as being at risk of developing the disease by comparing the amount or concentration determined in step (a) to the amount or concentration of NfL in a control, wherein an increased value of NfL relative to the control is indicative of the future development of the disease, as well as to uses related thereto.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: Methods are provided for the prevention, treatment and diagnosis of Alzheimer's disease, based on the glycosylation pattern of amyloid-beta peptides in body fluids and tissues.

Abstract: Methods are provided for the prevention, treatment and diagnosis of Alzheimer's disease, based on the glycosylation pattern of amyloid-beta peptides in body fluids and tissues.

Abstract: Methods are provided for the prevention, treatment and diagnosis of Alzheimer's disease, based on the glycosylation pattern of amyloid-beta peptides in body fluids and tissues.